

SCIENTIFIC PANEL ON NUTRITION, NOVEL FOODS AND FOOD ALLERGENS

MINUTES OF THE 115TH PLENARY MEETING

**Held on 25-26 May 2021 via web conference
(Agreed on 01 June 2021)**

Participants

■ Panel Members:

Jacqueline Castenmiller, Stefaan de Henauw, Karen Ildico Hirsch-Ernst, John Kearney, Helle Katrine Knutsen, Alexandre Maciuk¹, Inge Mangelsdorf, Harry J. McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Dominique Turck (Chair) and Marco Vinceti.

■ Hearing Experts:

Not Applicable

■ European Commission:

Stella D'Amore, Ivona Babic, Stephanie Bodenbach, Takis Daskaleros, Panagiota Filippou, and Rafael Perez-Berbejal.

■ EFSA:

NUTRI Unit: Valeriu Curtui, Domenico Azzollini, Janusz Ciok, Paolo Colombo, Agnès de Sesmaisons, Céline Dumas, Lucia Fabiani, Wolfgang Gelbmann, Leng Heng, Ruth Roldan Torres, Annamaria Rossi, Ariane Titz, Silvia Valtueña Martínez and Ermolaos Ververis.

DATA Unit: Zsuzsanna Horvath (item 8.1)

■ Others:

Anna Karin Lindroos and Eva Birgisdóttir Bryndís (as observers for item 8.1)

¹ Did not attend on the second day



1. Welcome and apologies for absence

The Chair welcomed the participants. No apologies were received.

2. Adoption of agenda

The agenda was adopted without changes.

3. Declarations of Interest of Scientific Panel members

In accordance with EFSA's Policy on Independence² and the Decision of the Executive Director on Competing Interest Management³, EFSA screened the Annual Declarations of Interest filled out by the Panel members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process, and no interests were declared orally by the members at the beginning of this meeting.

4. Agreement of the minutes of the 114th Plenary meeting

The **minutes** of the 114th Plenary meeting held on 07 May 2021 were agreed by written procedure on 10 May 2021.

5. Scientific outputs submitted for discussion and/or possible adoption

5.1 Draft opinion on the safety of Calcdiol monohydrate produced by chemical synthesis as a novel food (NF 2018/0402). Applicant: DSM Nutritional Products Ltd (EFSA-Q-2018-00514)

The draft opinion was presented. In particular, the Panel discussed the sections related to production process and characterisation, specifications, history of use, proposed uses, use levels and anticipated intake, nutritional information, ADME, toxicological information and allergenicity of the Novel Food. The opinion was adopted by the Panel on 25 May subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6660>

5.2 Draft opinion on the safety of Calcium Fructoborate as a novel food (NF 2019/0998). Applicant: VDF FutureCeuticals, Inc. (EFSA-Q-2019-00240)

The draft opinion was presented. The Panel reviewed and discussed the sections related to the identity, production process, compositional data, specifications, proposed uses and use levels, anticipated daily intake, nutritional information, ADME, toxicological information and allergenicity of the Novel Food. The opinion was adopted by the Panel on 25 May subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6661>

² http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf

³ http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf



5.3 Draft opinion on the safety of 3-fucosyllactose (3-FL) as a novel food (NF 2019/1321). Applicant: DuPont Nutrition & Biosciences ApS. (EFSA-Q-2019-00666)

The draft opinion was presented. The Panel reviewed and discussed the sections related to the identity, production process, compositional data, specifications, proposed uses and use levels, anticipated daily intake, nutritional information, toxicological data and allergenicity of the Novel Food. The opinion was adopted by the Panel on 25 May subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6662>

5.4 Draft opinion on the safety of frozen and dried formulations from migratory locust (*Locusta migratoria*) as a novel food (NF 2018/0803) Applicant: Fair Insects BV (A Protix Company) (EFSA-Q-2019-00115)

The draft opinion was presented. The Panel reviewed and discussed the sections related to the identity, production process, compositional data, specifications, proposed uses and use levels, history of use, anticipated daily intake, nutritional information, toxicological data and allergenicity of the Novel Food. The opinion was adopted by the Panel on 25 May subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6667>

5.5 Draft opinion on Affron® and increase in positive mood: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (0499_ES). Applicant: Pharmactive Biotech Products, SL (EFSA-Q-2020-00617)

The draft opinion was presented. The Panel reviewed and discussed the sections regarding the characterisation of the food, relevance of the claimed effect to human health, and the scientific substantiation of the claimed effect taking into consideration the data submitted in the present application including the applicant's replies to EFSA's stop-the-clock letters. The opinion was adopted by the Panel on 26 May subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6669>

5.6 Draft opinion on cetylated fatty acids as a novel food (NF 2020/1828). Applicant: Pharmanutra S.p.A (EFSA-Q-2020-00422)

The draft opinion was presented. The Panel reviewed all sections of the draft opinion and discussed in particular the results of a subchronic toxicity study. The opinion was adopted by the Panel on 26 May subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6670>

6. New mandates

Postponed.



7. Feedback from the Scientific Committee/Scientific Panels, EFSA, the European Commission

Postponed.

8. Other scientific topics for information and/or discussion

8.1 Draft Scientific opinion on the Tolerable Upper Intake Level of dietary sugars (EFSA-Q-2016-00414)

The draft opinion was open for comments by Panel members (all sections up to hazard characterisation) before the plenary meeting. Comments and suggested changes were discussed, and the draft opinion amended accordingly.

9. Any Other Business

The next plenary meeting of the NDA Panel is scheduled on 6-8 July 2021 via web conference.

The Panel was also informed that at the next plenary meeting (6 July) there will be the election of the Chair and Vice-Chairs. Experts were invited to express their interest to run for the election to the Unit in advance of the plenary meeting.

The Panel Chair, joined by all Members and EFSA Nutrition Unit, expressed their appreciation to John Kearney for his commitment and contribution to the work of the NDA Panel from July 2018 to June 2021.